BUSINESS
    Japan Firms Joining Fray in siRNA Drug Development; Takeda Could File as Early as FY2025
    By Tomohiro Osakabe June 6, 2023
    R&D is picking up speed in the field of small interfering RNA (siRNA) therapies. What has been the stronghold of Alnylam Pharmaceuticals has now seen more developers moving into the arena. Among Japanese players, furthest…

    LATEST

    Japan Unveils Healthcare DX Timeline, Set to Drive Secondary Data Usage by Drug Makers
    June 6, 2023
    The Japanese government on June 2 issued a timeline for the promotion of digital transformation in healthcare, including a plan to build a national data platform that would enable sharing and exchanging information on health…
    Japan Approves 1st Gene Panel Testing for IRD
    June 6, 2023
    Sysmex said on June 5 that it has won Japanese regulatory approval for PrismGuide IRD Panel System, the first gene panel testing system for inherited retinal dystrophy (IRD) in the country. The clearance was granted on May 31.PrismGuide IRD, a…
    Japan Likely to Approve Its 1st Cold Meds Containing Loxoprofen
    June 6, 2023
    Japan’s health ministry is expected to approve as early as September what would be the first cold medicines containing loxoprofen sodium hydrate in the country.The Pharmaceutical Affairs and Food Sanitation Council’s (PAFSC) committee on nonprescription drugs on June 5 gave…

    COLUMN

    Seven Recruitment Trends in 2023
    By Philip Carrigan

    As the post-pandemic world of work continues to evolve, so do recruiters’ strategies and tools for finding and engaging top talent. In 2023, we are seeing these seven trends:1. Employer branding is becoming an increasingly important factor in the recruitment…

    COMMENTARY

    Will Wegovy Lead the Way in Changing Picture of Obesity Treatment in Japan?
    By Sakura Kono

    Novo Nordisk’s weight-loss medication Wegovy (semaglutide) was approved in Japan in March. While it skipped the May round of reimbursement listing, physicians eagerly await the arrival of what would be the first new obesity drug in three decades. Other companies…

    MHLW Expert Panel on Comprehensive Measures for Pharmaceuticals

    Outline of Expert Panel Report Calls for New Forum to Discuss Generics’ Future, Revisiting of Spillover Rule
    By Tatsuya Otsuka

    Japan’s health ministry on April 27 presented an outline of a report to be compiled next month by its key…

    Chuikyo on Off-Year Drug Price Revision

    Healthcare Providers Rap Product Coverage of Off-Year Re-Pricing, Payers Hail Threshold: Chuikyo

    A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…

    Jiho Survey: FY2022 Drug Price Revision

    Authorized Generics Likely Speeding Up G1/G2 Price Cuts for Off-Patent Brands: Jiho Tally

    Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…

    FY2022 Drug Pricing Reform

    MHLW Unveils New List Prices for FY2022 Revision, 18 Off-Patent APIs Face Early “G1” Cuts

    Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…

    NEWS CATEGORY

    REGULATORY

    BUSINESS

    ORGANIZATION

    ACADEMIA